Drugs / ONO-3310
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07619157 | Jun 2026 → Nov 2027 expected | chronic kidney disease, type 2 diabetes mellitus | Ono Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ONO-3310 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07619157 ↗ |
| Route | Oral | “Single oral dose of ONO-3310 to HV” NCT07619157 ↗ |